Basilea Pharmaceutica AG

BATS-CHIXE:BSLNz Stock Report

Market Cap: CHF 510.3m

Basilea Pharmaceutica Valuation

Is BSLNz undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSLNz when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BSLNz (CHF41.95) is trading below our estimate of fair value (CHF42.08)

Significantly Below Fair Value: BSLNz is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSLNz?

Key metric: As BSLNz is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BSLNz. This is calculated by dividing BSLNz's market cap by their current revenue.
What is BSLNz's PS Ratio?
PS Ratio3.4x
SalesCHF 149.02m
Market CapCHF 510.30m

Price to Sales Ratio vs Peers

How does BSLNz's PS Ratio compare to its peers?

The above table shows the PS ratio for BSLNz vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
OXB Oxford Biomedica
4.6x21.0%UK£447.3m
BVXP Bioventix
14.4xn/aUK£195.7m
GNS Genus
1.7x3.5%UK£1.1b
AVCT Avacta Group
7.8x0.4%UK£182.9m
BSLNz Basilea Pharmaceutica
3.4x6.0%CHF 510.3m

Price-To-Sales vs Peers: BSLNz is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (7.2x).

Price to Sales Ratio vs Industry

How does BSLNz's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
BSLNz Basilea Pharmaceutica
 3.4x6.0%US$575.06m
GNS Genus
1.7x3.5%US$1.39b
OXB Oxford Biomedica
4.6x21.0%US$562.82m
No. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a37.0%
BSLNz Basilea Pharmaceutica
 3.4x20.1%US$575.06m
No more companies

Price-To-Sales vs Industry: BSLNz is good value based on its Price-To-Sales Ratio (3.4x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is BSLNz's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSLNz PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.4x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: BSLNz is expensive based on its Price-To-Sales Ratio (3.4x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSLNz forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 41.95
CHF 77.25
+84.1%
31.6%CHF 120.00CHF 52.00n/a6
Nov ’25CHF 43.48
CHF 74.87
+72.2%
35.7%CHF 120.00CHF 44.20n/a6
Oct ’25CHF 45.45
CHF 73.20
+61.1%
32.8%CHF 110.00CHF 44.20n/a6
Sep ’25CHF 46.10
CHF 72.37
+57.0%
32.0%CHF 110.00CHF 44.20n/a6
Aug ’25CHF 39.80
CHF 71.20
+78.9%
30.5%CHF 105.00CHF 44.20n/a6
Jul ’25CHF 39.30
CHF 71.20
+81.2%
30.5%CHF 105.00CHF 44.20n/a6
Jun ’25CHF 43.80
CHF 70.58
+61.1%
31.9%CHF 105.00CHF 40.50n/a6
May ’25CHF 39.65
CHF 70.58
+78.0%
31.9%CHF 105.00CHF 40.50n/a6
Apr ’25CHF 37.63
CHF 69.08
+83.6%
30.6%CHF 105.00CHF 40.50n/a6
Mar ’25CHF 35.10
CHF 69.08
+96.8%
30.6%CHF 105.00CHF 40.50n/a6
Feb ’25CHF 33.00
CHF 64.38
+95.1%
24.7%CHF 85.00CHF 40.50n/a4
Jan ’25CHF 35.40
CHF 70.70
+99.7%
26.5%CHF 91.00CHF 40.50n/a5
Dec ’24CHF 34.70
CHF 75.68
+118.1%
19.8%CHF 91.00CHF 57.70n/a4
Nov ’24CHF 35.45
CHF 73.28
+106.7%
20.1%CHF 91.00CHF 52.00CHF 43.486
Oct ’24CHF 40.90
CHF 70.44
+72.2%
21.7%CHF 91.00CHF 52.00CHF 45.457
Sep ’24CHF 47.90
CHF 70.44
+47.1%
21.7%CHF 91.00CHF 52.00CHF 46.107
Aug ’24CHF 43.70
CHF 70.44
+61.2%
21.7%CHF 91.00CHF 52.00CHF 39.807
Jul ’24CHF 41.85
CHF 67.18
+60.5%
21.0%CHF 91.00CHF 52.00CHF 39.306
Jun ’24CHF 45.60
CHF 67.18
+47.3%
21.0%CHF 91.00CHF 52.00CHF 43.806
May ’24CHF 43.30
CHF 72.07
+66.4%
20.8%CHF 91.00CHF 52.00CHF 39.656
Apr ’24CHF 50.20
CHF 74.80
+49.0%
18.4%CHF 91.00CHF 52.00CHF 37.635
Mar ’24CHF 52.30
CHF 68.98
+31.9%
26.2%CHF 91.00CHF 39.90CHF 35.106
Feb ’24CHF 48.85
CHF 73.82
+51.1%
34.7%CHF 120.00CHF 39.90CHF 33.006
Jan ’24CHF 45.80
CHF 69.15
+51.0%
26.2%CHF 91.00CHF 39.90CHF 35.406
Dec ’23CHF 49.75
CHF 68.58
+37.8%
28.9%CHF 91.00CHF 39.90CHF 34.705
Nov ’23CHF 46.80
CHF 74.48
+59.2%
34.4%CHF 120.00CHF 39.90CHF 35.456

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.75

7D

0.4%

1Y

-5.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

2.4%

1Y

12.5%